Rice Hall James & Associates, LLC Exelixis, Inc. Transaction History

Rice Hall James & Associates, LLC

  • $1.69 Billion
  • Q3 2024

A detailed history of Rice Hall James & Associates, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 20,766 shares of EXEL stock, worth $739,477. This represents 0.03% of its overall portfolio holdings.

Number of Shares
20,766
Previous 21,411 3.01%
Holding current value
$739,477
Previous $481,000 11.85%
% of portfolio
0.03%
Previous 0.03%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024
SELL
$21.96 - $27.6 $14,164 - $17,802
-645 Reduced 3.01%
20,766 $538,000
Q2 2024

Aug 07, 2024
SELL
$20.34 - $23.73 $5,837 - $6,810
-287 Reduced 1.32%
21,411 $481,000
Q1 2024

Apr 23, 2024
SELL
$20.17 - $23.93 $321,650 - $381,611
-15,947 Reduced 42.36%
21,698 $514,000
Q4 2023

Feb 08, 2024
SELL
$19.25 - $24.13 $1,424 - $1,785
-74 Reduced 0.2%
37,645 $903,000
Q3 2023

Nov 02, 2023
SELL
$19.04 - $22.74 $15,232 - $18,192
-800 Reduced 2.08%
37,719 $824,000
Q2 2023

Jul 24, 2023
SELL
$18.17 - $20.48 $748,295 - $843,427
-41,183 Reduced 51.67%
38,519 $736,000
Q1 2023

May 11, 2023
BUY
$16.3 - $19.41 $63,390 - $75,485
3,889 Added 5.13%
79,702 $1.55 Million
Q4 2022

Jan 27, 2023
SELL
$14.96 - $17.39 $92,422 - $107,435
-6,178 Reduced 7.53%
75,813 $0
Q3 2022

Nov 01, 2022
SELL
$15.68 - $22.27 $87,729 - $124,600
-5,595 Reduced 6.39%
81,991 $1.29 Million
Q2 2022

Aug 08, 2022
BUY
$17.44 - $23.16 $5,022 - $6,670
288 Added 0.33%
87,586 $1.82 Million
Q1 2022

May 05, 2022
SELL
$17.03 - $22.67 $74,165 - $98,727
-4,355 Reduced 4.75%
87,298 $1.98 Million
Q3 2021

Nov 09, 2021
SELL
$16.3 - $21.14 $43,129 - $55,936
-2,646 Reduced 2.81%
91,653 $1.94 Million
Q2 2021

Jul 29, 2021
SELL
$17.95 - $25.56 $91,545 - $130,356
-5,100 Reduced 5.13%
94,299 $1.72 Million
Q1 2021

May 14, 2021
SELL
$20.53 - $25.22 $117,021 - $143,754
-5,700 Reduced 5.42%
99,399 $2.25 Million
Q4 2020

Feb 16, 2021
SELL
$18.39 - $24.8 $287,785 - $388,095
-15,649 Reduced 12.96%
105,099 $2.11 Million
Q3 2020

Nov 16, 2020
SELL
$20.67 - $26.94 $134,851 - $175,756
-6,524 Reduced 5.13%
120,748 $2.95 Million
Q2 2020

Aug 14, 2020
SELL
$16.46 - $27.42 $42,746 - $71,209
-2,597 Reduced 2.0%
127,272 $3.02 Million
Q1 2020

May 15, 2020
BUY
$14.46 - $21.8 $114,595 - $172,765
7,925 Added 6.5%
129,869 $2.24 Million
Q4 2019

Jan 29, 2020
BUY
$15.15 - $18.89 $473,104 - $589,896
31,228 Added 34.42%
121,944 $2.15 Million
Q3 2019

Oct 30, 2019
BUY
$17.68 - $22.65 $1.6 Million - $2.05 Million
90,716 New
90,716 $1.6 Million

Others Institutions Holding EXEL

# of Institutions
501
Shares Held
244M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email